

## BSW Formulary Update – Following APC July 2021 meeting

### New and Updated Prescribing Guidelines/Shared care Guideline

- **Updated – BSW Management of Infections in Primary Care (Full) and (Child - Quick Reference Guide)** updated to include the [MHRA DSU for chloramphenicol](#) which states chloramphenicol eye drops can be safely administered to children aged 0 to 2 years where antibiotic eye drop treatment is indicated.

### New additions to the BSWformulary

- [Ferric Maltol 30mg oral capsules \(Feraccru®\)](#) added for the treatment of iron deficiency anaemia ONLY for use in adult patients with inflammatory bowel disease where 2 or more different oral iron salts have been trialled for an adequate period of time but are not tolerated and the next step in treatment would be intravenous iron. **GREEN TLS**. See [BSW Pathway for use of Ferric Maltol](#) for further information. While there is no robust evidence to demonstrate clinical advantage of ferric maltol over IV iron, and correction of iron deficiency via this route would not be as rapid, it may be a more acceptable therapy route for patients and may help to reduce patients needing to attend hospital for IV iron. **Feraccru is significantly more expensive than conventional oral iron salts. Formulary status will be reviewed after the first 12 months (July 2022)** to determine if inclusion on the BSWformulary has achieved the expected outcomes.
- [Bempedoic acid 180mg tablets](#) and [Bempedoic acid/Ezetemibe 180mg/10mg tablets](#) added to BSWformulary with **Amber TLS** for treating primary hypercholesterolaemia or mixed dyslipidaemia in line with [NICE TA694](#). **BSW guidance to support prescribing in primary care is being developed.**
- [Calcium folinate](#) Tablet formulation added to existing entry (**RED TLS**)
- [Flupentixol decanoate injection](#) Amended to include different brands used across BSW

### Other BSWformulary website updates

In line with [NICE MPG1:Developing and updating local formularies](#), the [BSWAPC](#) discusses newly published NICE TAs as a standing agenda item in its meetings. Due to the complexity of commissioning for drugs used in haematology/oncology indications, Chapter 8 of the BSWformulary (Malignant disease and immunosuppression) is not kept up to date with links to NICE TAs. For the most accurate information on how these drugs are accessed and funded locally for our patients for haematology/oncology indications, please contact pharmacy within your acute Trust or email [bswccg.formulary@nhs.net](mailto:bswccg.formulary@nhs.net)

The following drugs have been added with **RED TLS** for use within applicable Trusts (RUH/SFT/GWH) in line with the relevant NICE guidance:

[Benralizumab 30mg/1ml solution for injection](#) NICE TA565

[Erenumab 70mg/1ml and 140mg/1ml solution for injection](#) NICE TA682 (see also [BSW Chronic Migraine Pathway for Adults](#))

[Filgotinib 100mg and 200mg tablets](#) NICE TA676

[Anakinra 100mg/0.67ml solution for injection](#) NICE TA685

[Andexanet alfa 200mg powder for solution for infusion](#) NICE TA697

### **What the BSW CCG formulary team are currently working on**

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSW formulary across primary and secondary care.
- Updating the BSW primary care antibiotic guidance in line with NICE updates including treatment of acne, the treatment of Clostridioides difficile infection and reviewing TLS and primary care prescribing of rifampicin.
- Working with AWP on an oral antipsychotic SCA.
- Reviewing the national SCA consultations by RMOC.
- Updating the HRT pathway and reviewing Testosterone in HRT policy.
- Reviewing policy on use of Continuous Glucose Monitoring (CGM).
- Reviewing COPD guidance including updates to the primary guidance on rescue packs, COPD guidance and COPD inhaler guide.

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswccg.formulary@nhs.net](mailto:bswccg.formulary@nhs.net)*